Seroatlas · Human Serome Atlas

TGFB1

Transforming growth factor beta-1 proprotein

Also known as: TGFB1_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01137
Gene
TGFB1
Canonical length
390 aa
Protein class
Human disease related genes, Predicted secreted proteins
Quaternary structure
Homodimer

OverviewNCBI Gene

No narrative summary is available for TGFB1 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

390 residues, UniProt reviewed canonical sequence.

>P01137|TGFB1
     1  MPPSGLRLLP LLLPLLWLLV LTPGRPAAGL STCKTIDMEL VKRKRIEAIR GQILSKLRLA
    61  SPPSQGEVPP GPLPEAVLAL YNSTRDRVAG ESAEPEPEPE ADYYAKEVTR VLMVETHNEI
   121  YDKFKQSTHS IYMFFNTSEL REAVPEPVLL SRAELRLLRL KLKVEQHVEL YQKYSNNSWR
   181  YLSNRLLAPS DSPEWLSFDV TGVVRQWLSR GGEIEGFRLS AHCSCDSRDN TLQVDINGFT
   241  TGRRGDLATI HGMNRPFLLL MATPLERAQH LQSSRHRRAL DTNYCFSSTE KNCCVRQLYI
   301  DFRKDLGWKW IHEPKGYHAN FCLGPCPYIW SLDTQYSKVL ALYNQHNPGA SAAPCCVPQA
   361  LEPLPIVYYV GRKPKVEQLS NMIVRSCKCS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TGFB1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.36
Highest tissue expression
100 nTPM

Expression across tissuesHPA

Tissue

  • blood vessel: 100 nTPM
  • spleen: 87 nTPM
  • bone marrow: 78 nTPM
  • lung: 62 nTPM
  • esophagus: 52 nTPM
  • cervix: 47 nTPM

Single-cell type

  • platelets: 2,842 nCPM
  • extravillous trophoblasts: 829 nCPM
  • megakaryocytes: 822 nCPM
  • nk-cells: 521 nCPM
  • neutrophils: 498 nCPM
  • pdcs: 484 nCPM

Immune cell

  • eosinophil: 3.9 nTPM
  • neutrophil: 2.4 nTPM
  • intermediate monocyte: 1.2 nTPM
  • basophil: 1.1 nTPM
  • plasmacytoid DC: 0.9 nTPM
  • total PBMC: 0.9 nTPM

Brain region

  • medulla oblongata: 54 nTPM
  • thalamus: 43 nTPM
  • spinal cord: 42 nTPM
  • white matter: 40 nTPM
  • pons: 39 nTPM
  • hypothalamus: 35 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TGFB1.

Disease | AllUniProt

Conditions TGFB1 is implicated in, by any mechanism.

  • Camurati-Engelmann disease (CAEND) MIM:131300
  • Inflammatory bowel disease, immunodeficiency, and encephalopathy (IBDIMDE) MIM:618213

Disease | GeneticClinVar

11 pathogenic / likely-pathogenic of 540 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | AutoantibodyPubMed

Conditions in which antibodies against TGFB1 are reported. Each links to that disease's full target list.

ReferencesPubMed · IEDB

Publications for TGFB1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

15 publications

Show 10 more

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.61
gnomAD pLI
0.04
gnomAD missense Z
1.86
DepMap mean gene effect
0.06
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TGFB1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TGFB1 as an antibody target. Whether an autoantibody or antibody against TGFB1 could matter depends on whether native TGFB1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TGFB1 is annotated as secreted, so native TGFB1 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label TGFB1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TGFB1. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...